The TGA says a recently
completed review of pioglitazone
(Actos) has found that it has a
favourable long-term risk-benefit
profile, after earlier identification of
an increased risk of bladder cancer
with long-term use of the drug.
That’s one of the items in the
newest edition of its Medicines
Safety Update which also includes
articles on duloxetine and serotonin
syndrome, minocycline and
intracranial hypertension plus
5-alpha reductase inhibitors and
the risk of high-grade prostate
cancer.
The update is now available
online by CLICKING HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Dec 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Dec 13
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.